Trastuzumab Emtansine Delays Progression of HER2+ Metastatic Breast Cancer

TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in In the News

The antibody-guided drug conjugate trastuzumab emtansine (T-DM1) as initial therapy prolonged progression-free survival (PFS) for patients with HER2-positive metastatic breast cancer compared with docetaxel plus trastuzumab, according to trial results reported at the European Multidisciplinary Cancer Conference.

The conjugate delivers trastuzumab directly to tumor cells by attaching the drug to DM1 using a stable linker. This limits the drug’s exposure to normal cells, thus producing fewer side effects than the drug delivers through traditional means.

The phase 2 trial randomized 137 patients who were chemotherapy-naïve to either T-DM1 or trastuzumab plus docetaxel chemotherapy. Median PFS was 14.2 months in the T-DM1 group compared with 9.2 months in the trastuzumab/docetaxel group. In the T-DM1 arm, only 7.2% of patients discontinued treatment because of side effects; 28.8% discontinued treatment in the trastuzumab/docetaxel arm.

Related Items
Pembrolizumab Approved for Patients with Head and Neck Cancer
In the News: Oncology - August 2016 published on August 10, 2016 in In the News
Beth Faiman Nominated for Leukemia & Lymphoma Society Woman of the Year
TON March 2016 Vol 9 No 2 published on March 22, 2016 in In the News
CYP2D6 Genotyping Fails to Predict Effectiveness of Tamoxifen
Alice Goodman
TOP - April 2012, Vol 5, No 2 published on April 27, 2012 in In the News
"Chemo Brain" Can Persist for 2 Decades
TOP - April 2012, Vol 5, No 2 published on April 27, 2012 in In the News
Chronic Kidney Disease and Risk of Kidney Cancer
TON - MARCH 2012 VOL 5, NO 2 published on April 27, 2012 in In the News
CYP2D6 Genotyping Fails to Predict Effectiveness of Tamoxifen
Alice Goodman
TON - April 2012, Vol 5, No 3 published on April 27, 2012 in In the News
“Chemo Brain” Can Persist for 2 Decades
TON - April 2012, Vol 5, No 3 published on April 27, 2012 in In the News
GIST Outside GI Tract Has Poor Prognosis
TON - April 2012, Vol 5, No 3 published on April 27, 2012 in In the News
Bone Biomarker Identified for Metastatic Prostate Cancer
Alice Goodman
TON - MARCH 2012 VOL 5, NO 2 published on April 10, 2012 in In the News
Protocol-Ineligible Patients With Metastatic Renal Cell Carcinoma Fare Worse Than Those Eligible for Clinical Trials
TON - MARCH 2012 VOL 5, NO 2 published on April 10, 2012 in In the News
Last modified: January 11, 2018